BTIG Defends bluebird bio (BLUE) Amid ASH Abstracts Sell-Off
- Wall Street lower as oil snaps four-day rally
- Equinix (EQIX) Announces $3.6B Acquisition of Data Center Portfolio from Verzion (VZ)
- Deal Progress Said to Slow as Johnson & Johnson (JNJ) Puts Actelion (ALIOY) Under Microscope - Source
- Trump Wants to Cancel New Air Force One Order with Boeing (BA)
- Roper Industries (ROP) to acquire Deltek in $2.8B Deal
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
BTIG is out in defense of bluebird bio (Nasdaq: BLUE) following release of ASH abstracts earlier this morning. The firm rates bluebird at Buy with a price target of $83.
The firm commented,
BLUE has experienced a significant sell-off as a result of weak responses from older Sickle-cell Disease (SCD) patients treated within the HGB-206 study. We disagree with the market reaction, as our conversation with management today reconfirmed our belief that the company has a credible opportunity within SCD via improvements to the manufacturing and dosing processes of LentiGlobin. We reiterate our Buy rating and $82 PT, and would aggressively buy on todays sell-off.
Hurdle with SCD is the Dosing and not the Therapeutic: As demonstrated with patient 1204 who is producing ~53% HbA at 18-months post-infusion and discontinued transfusions 3-months after treatment without symptomatic crises. Patient 1204 is 13yrs old, in much better condition compared to the 7 patients with poor responses from the HGB-206 cohort that ranged in age of 18 – 42yrs. Overall we feel confident that the dimension of age can be overcome with the new manufacturing processes.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- bluebird bio (BLUE) Updates on HSC Programs; Says First Patient Enrolled in Northstar-2 Trial
- UPDATE: Stifel Upgrades Green Plains Partners LP (GPP) to Buy
- Oppenheimer Raises Price Target on Bob Evans Farms (BOBE) Following 2Q EPS Beat
Create E-mail Alert Related CategoriesAnalyst Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!